Pfizer shares top-line data from pivotal study of pentavalent meningococcal vaccine in adolescents

Aiming to extend its vaccine empire, Pfizer (NYSE:PFE) has announced that its meningococcal vaccine (MenABCWY) candidate met primary and secondary endpoints in a Phase 3 study.

The NCT04440163 study tested the vaccine in healthy individuals between the ages of 10 and 25.

The vaccine candidate demonstrated non-inferiority to the licensed vaccines Trumenba and Menveo for the five meningococcal serogroups that cause the most invasive meningococcal disease: serogroups A, B, C, W and Y.

If approved, the vaccine could be the first to protect against the five meningococcal serogroups.

Pfizer plans on filing for U.S. approval in the fourth quarter of 2022. The company also plans to seek authorization for the vaccine in other regions.

At present, FDA has approved discrete MenACWY and MenB vaccines.

The NCT04440163 study randomly assigned participants to receive two doses of MenABCWY or two doses of Trumenba plus one dose of Menveo. Pfizer is …

Read more
  • 0